213 related articles for article (PubMed ID: 23871798)
1. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Stoeckle M; Holbro A; Arnold A; Neumayr A; Weisser M; Blum J
Acta Trop; 2013 Oct; 128(1):168-70. PubMed ID: 23871798
[TBL] [Abstract][Full Text] [Related]
2. Mucosal Leishmania infantum infection.
Richter J; Hanus I; Häussinger D; Löscher T; Harms G
Parasitol Res; 2011 Sep; 109(3):959-62. PubMed ID: 21499751
[TBL] [Abstract][Full Text] [Related]
3. Mucosal leishmaniasis and miltefosine.
Tuon FF; Amato VS
Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
[No Abstract] [Full Text] [Related]
4. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients.
Aliaga L; Cobo F; Mediavilla JD; Bravo J; Osuna A; Amador JM; Martín-Sánchez J; Cordero E; Navarro JM
Medicine (Baltimore); 2003 May; 82(3):147-58. PubMed ID: 12792301
[TBL] [Abstract][Full Text] [Related]
5. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
6. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.
Soto J; Rea J; Valderrama M; Toledo J; Valda L; Ardiles J; Berman J
Am J Trop Med Hyg; 2009 Sep; 81(3):387-9. PubMed ID: 19706901
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment.
Neumayr AL; Walter C; Stoeckle M; Braendle N; Glatz K; Blum JA
J Travel Med; 2012; 19(2):124-6. PubMed ID: 22414039
[TBL] [Abstract][Full Text] [Related]
9. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Monge-Maillo B; López-Vélez R
Clin Infect Dis; 2015 May; 60(9):1398-404. PubMed ID: 25601455
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by
Calvopina M; Jijon S; Serrano E; Kato H
Am J Trop Med Hyg; 2020 Aug; 103(2):752-755. PubMed ID: 32524951
[TBL] [Abstract][Full Text] [Related]
12. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.
Dorlo TP; van Thiel PP; Schoone GJ; Stienstra Y; van Vugt M; Beijnen JH; de Vries PJ
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1436. PubMed ID: 22180803
[TBL] [Abstract][Full Text] [Related]
14. The histological spectrum of non-granulomatous localized mucosal leishmaniasis caused by Leishmania infantum.
Cobo F; Aliaga L; Talavera P; Concha A
Ann Trop Med Parasitol; 2007 Dec; 101(8):689-94. PubMed ID: 18028730
[TBL] [Abstract][Full Text] [Related]
15. [Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Garcia Bustos MF; Barrio A; Parodi C; Beckar J; Moreno S; Basombrio MA
Medicina (B Aires); 2014; 74(5):371-7. PubMed ID: 25347898
[TBL] [Abstract][Full Text] [Related]
16. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Bhattacharya A; Ouellette M
EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
[No Abstract] [Full Text] [Related]
17. Co-infection of mucosal leishmaniasis and extra pulmonary tuberculosis in a patient with inherent immune deficiency.
Rathnayake D; Ranawake RR; Sirimanna G; Siriwardhane Y; Karunaweera N; De Silva R
Int J Dermatol; 2010 May; 49(5):549-51. PubMed ID: 20534090
[TBL] [Abstract][Full Text] [Related]
18. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Manna L; Vitale F; Reale S; Picillo E; Neglia G; Vescio F; Gravino AE
Vet J; 2009 Dec; 182(3):441-5. PubMed ID: 18818112
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
[TBL] [Abstract][Full Text] [Related]
20. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
